cyrilzakka/clinical-trials huggingface dataset:
Efficacy of Kinesiotape on Treatment of Nonspecific Cardiac Chest Pain

purpose of the study To investigate the effect of Kinesio-tape on treatment of nonspecific cardiac chest pain

Nonspecific musculoskeletal chest pain is a major health problem and is a very common and functionally limiting pain complaint. Patients with this problem complain also of significant disability of daily living activities and lost productivity.

The clinical symptom of anterior chest pain generally elicits a long list of diagnoses, when cardiac and pleural conditions are excluded, conditions that affect the musculoskeletal system become important considerations.

The musculoskeletal structures of the thoracic wall and the neck are relatively common sources of chest pain, hypersensitive loci, named myofascial trigger points in the literature, are associated with the Pathophysiology and clinical manifestation of myofascial pain, Rhomboid Muscle trigger point can be a distressing cause of chest pain which can be effectively taken care of by Ischemic compression therapy. Rhomboid muscle trigger points are one of the major causes of nonspecific cardiac chest pain that make the patient seek treatment in different medical health care, but still there is a lake of scientific evidence that supports a particular treatment. Conducting the current study will find an additional solution for this problem.

Kinesio-Taping a technique highly appropriate in patients with soft tissue involvement and plays a major role in the deactivation of trigger points, KT is theorized to have several functions: (1) restoring correct muscle function by supporting weakened muscles, (2) reducing congestion by improving the flow of blood and lymphatic fluid, (3) decreasing pain by stimulating neurological system, (4) correcting misaligned joints by retrieving muscle spasm, and (5) enhancing proprioception through increased stimulation to cutaneous mechanoreceptors

Eligibility Criteria:
Inclusion Criteria:

* 30 subjects from both sexes with nonspecific cardiac chest pain 2- Rhomboid trigger point 3-All subjects range from 7 to 9 on VAS. 4-Age range from 20-35. 5- All subjects will complain from limited shoulder ROM

Exclusion Criteria:

* Acute coronary syndrome/ ischemic heart disease 2-Pleurisy 3-Pulmonary lessons like(COPD) Chronic Obstructive Pulmonary Disease,( COAD) Chronic Obstructive Airway Disease and Bronchiectasis, 4-Costochondritis, ' 5-Teitze syndrome, 6-Chest wall syndrome 7-Rheumatologic conditions, 8-Infections in the chest wall 9-Gastro-intestinal problems and 10-Neoplastic disorders
POPLITEAL SCIATIC NERVE BLOCK FOR DIABETIC FOOT SURGERIES

Popliteal Sciatic nerve block is a regional technique that provides safe and reliable perioperative anesthesia and analgesia of lower leg and foot used in diabetic patients. Different additives have been used with local anaesthetics to achieve dense and prolonged block. Magnesium sulfate possesses analgesic properties owing to its effect on NMDA receptors.


Eligibility Criteria:
Inclusion Criteria:

* (ASA) II or III
* scheduled for diabetic foot surgeries.

Exclusion Criteria:

* Patients who refused the anaesthetic technique,
* whose BMI ≥ 35 kg/ m2,
* unable to properly describe postoperative pain to investigator (dementia, delirium, psychiatric and neurological disorders),
* patients with coagulopathy, skin infection at the site of injection,
* preoperative use of opioid or non-steroidal anti-inflammatory drugs,
* allergy or contraindication to studied medication
Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)

The objective of this trial is to compare an individually optimized dose of the lisuride TTS patch against placebo and against an individually optimized dose of oral ropinirole (active- and placebo-controlled design) in idiopathic and uremic RLS patients with regard to efficacy, safety, and quality of life.

Approximately 300 patients will be randomized to receive either lisuride, ropinirole or placebo in a 2:1:1 fashion. After completion of 12 weeks of double-blind treatment, eligible patients will have the option to continue treatment with the lisuride patch for further 36 weeks in an open-label extension of the study.

Primary outcome: Changes in the total score of the International Restless Legs Severity Scale (IRLS) from baseline to end of double-blind treatment (12 weeks) will be used as primary efficacy outcome measure.

Secondary objectives are to evaluate quality of life, safety and tolerability. After the double-blind period, long-term efficacy of lisuride will be assessed for further 36 weeks in an open-label extension of the study.

Eligibility Criteria:
Inclusion Criteria:

* Idiopathic or uremic RLS
* RLS Diagnostic Index (RLS-DI) \> 10
* Total score in the IRLS Rating Scale ≥ 15 at baseline
* No previous treatment for RLS or insufficient current therapy

Exclusion Criteria:

* Secondary RLS, e.g. due to iron deficiency (exception: uremia)
* History or presence of sleep disorders other than RLS
The Reliability, Validity, and Responsiveness of the Static Balance Test in Patients With Multiple Sclerosis.

The aim of the study is to investigate reliability, validity, and responsiveness of the Static Balance Test in patients with Multiple Sclerosis.

At baseline, the Static Balance Test, Berg Balance Scale, Timed Up and Go test, Functional Reach Test, Four Square Step Test, and One-legged Stance Test is applied to the Multiple Sclerosis group. The Static Balance Test is repeated after seven days from the first application in patients with Multiple Sclerosis. Healthy controls are going to perform only the Static Balance Test.

Eligibility Criteria:
Inclusion Criteria:

* at least 18 years,
* neurologist-diagnosed Multiple Sclerosis,
* Expanded Disability Status Scale (EDSS) score \< 7,
* able to walk 10 m with or without aids,
* no MS exacerbation within the last 2 months,
* use of stable medication in the last 2 months,

Exclusion Criteria:

* other neurologic disorder,
* Pregnancy,
* orhopedic problems iaffecting gait and stance,
* visual, auditory, orientational problems that could affect study results,
* Cardiovascular, pulmonary, and humoral disease.
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem cells to replace the tumor cells.

This randomized phase II trial studies how well giving low dose total-body irradiation (TBI) with anti-thymocyte globulin followed by donor peripheral blood stem cell transplant (PBSCT) works in treating patients with hematologic malignancies. Giving reduced intensity total-body irradiation and anti-thymocyte globulin before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving total-body irradiation together with antithymocyte globulin before transplant may stop this from happening.

Eligibility Criteria:
Inclusion Criteria:

* Patients with hematological malignancies for which allogeneic stem cell transplantation indicated including non-Hodgkin lymphoma (NHL), multiple myeloma (MM), acute myeloid leukemia (AML), Hodgkin lymphoma (HD), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS)
* Patients with HLA compatible related or unrelated stem cell donor, willing and able to serve as an allogenic HSC donor. Unrelated donors have to be matched at HLA-A, B, C and DRB1 loci. A single locus mismatch will be tolerated in the event a more closely matched donor is not available.
* Patients age \>/=40 to \</=70 with an ECOG performance status \< 2
* Patients between 18 and 40 years of age will be eligible only if they have co-morbidities precluding conventional allogeneic transplantation with full intensity myeloablative conditioning
* Adequate cardiac, pulmonary, renal and hepatic function for transplant
* Negative serology for HIV
* Negative serum pregnancy test
* Patients who have received therapeutic radiation to a localized field will be eligible, provided critical structure tolerance doses have not been exceeded
* Patients who have had prior myeloablative autologous transplant will be eligible

Exclusion Criteria:

* Evidence of uncontrolled viral, fungal, bacterial infection
* Evidence of active meningeal or CNS disease
* Prior therapy with rabbit ATG, prior treatment with equine ATG is allowed if more than 3 months ago
* Breast feeding mothers are excluded
Bioequivalency Study of 600 mg Oxcarbazepine Tablets Under Fasting Conditions

The objective of this study was to assess the bioequivalence of a potential generic 600 mg oxcarbazepine tablet formulation compared with Novartis Pharmaceutical's 600 mg oxcarbazepine tablet, Trileptal, following a single 600 mg dose administered under fasting conditions.


Eligibility Criteria:
Inclusion Criteria:

* No clinically significant abnormal finding on the physical examination, medical history, or clinical labratory results duirng screening

Exclusion Criteria:

* Positive test for HIV, Hepatitis B, or Hepatitis C.
* Treatment with known enzyme altering drugs.
* History of allergic or adverse response to oxcarbazepne or any other comparable or similar product.
Clearance of Inflammatory Cytokines During Renal Replacement Therapy Using the EMIC®2 Filter

This study will be conducted in patients with sepsis and acute kidney injury needing renal replacement therapy.

The aim is to investigate whether continuous renal replacement therapy with the EMIC®2 filter leads to removal of pro-inflammatory middle molecular weight cytokines from the blood.

In patients with acute kidney injury (AKI) and sepsis requiring renal replacement therapy, the investigators aim to determine whether continuous veno-venous haemodialysis with an EMiC®2 filter leads to clearance of the following mediators Interleukin (IL) -1 alpha, IL-1 beta, IL-2, IL- 4, IL-6, IL-8, IL-10, Tissue necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), Interferon gamma, Monocyte chemotactic protein-1 and epidermal growth factor.

Eligibility Criteria:
Inclusion Criteria:

* adult patients (≥18 years) in the Critical Care Unit with AKI and sepsis
* clinical decision that citrate based continuous veno-venous haemodialysis (CVVHD) is necessary

Exclusion Criteria:

* lack of consent
* pre-existing dialysis dependent renal failure
* life expectancy \<24 hours
* patients with haemoglobin \<7g/dL (unless transfused for clinical reasons)
* need for extracorporeal membrane oxygenation (ECMO)
Effectivity and Safety of Metronidazole 1% Cream in Rosacea Therapy

Rosacea is a chronic inflammatory disease of the central facial region, which can also occur in the neck and chest regions. Microbes that play a role in rosacea are Demodex folliculorum and Helicobactor pylori. On the skin with rosacea have decreased skin barrier function. This clinical study will compare the effectiveness and safety of metronidazole 1% cream as the main therapy in rosacea patients. Participants who will become research subjects are women and men aged 18-60 years who meet the inclusion criteria. Research subjects were divided into 2 groups. The control group will use placebo cream (without the drug substance) and the comparison group will use metronidazole 1% cream.

This study is an experimental study with a double-blind randomized controlled trial (RCT) design for researchers and subjects in male and female patients aged 18-60 years who meet the inclusion criteria. This study used 1% metronidazole cream and placebo cream as a comparison. The creams will then be coded as cream A and cream B. This research will be conducted in two places, namely the Dermatology and Venereology Polyclinic, Division of Cosmetic Dermatology, Cipto Mangunkusumo Hospital (RSCM) and the Dermatology and Venereology Polyclinic, University of Indonesia Hospital (RSUI). The control group will use placebo cream (without the drug substance) and the comparison group will use metronidazole 1% cream. All participants will be evaluated twice on days 28 and days 56. Evaluation of response to therapy that will be assessed includes the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination.

Eligibility Criteria:
Inclusion Criteria:

* Male and Female, aged 18-60 years
* Diagnosed with rosacea
* The patient agreed to participate in the study and signed a inform consent

Exclusion Criteria:

* Taking corticosteroid therapy (oral or topical)
* Patients with a history of using topical therapy on the face within one month before the study
* Taking metronidazole, clarithromycin, or azithromycin within one month before the study
* Patients who are frequently exposed to ultraviolet (UV) light
* Pregnant or breastfeeding
* Patient and/or family do not agree to participate

Drop Out Criteria:

* Pass away during the clinical trial
* Research subjects were not present when scheduling the action or did not comply with the research protocol.
* Research subjects were not present when scheduling the action or did not comply with the research protocol.
* Suffer from coronavirus disease 2019 (COVID-19) at any time during the trial
* Experience major adverse event(s) caused by topical products or treatments given in the clinical trial (e.g. allergic drug eruption or contact dermatitis). The participants will receive appropriate management if such event occurs
Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler

The aim of this pilot study is to assess the methodology, practical arrangements and pulmonary absorption with charcoal blockage for the future bioequivalence studies. In addition, PK of budesonide and formoterol after administration from 2 different batches of Symbicort TH is compared with each other.


Eligibility Criteria:
Inclusion Criteria:

* Good general health ascertained by detailed medical history, and laboratory and physical examinations
* Finnish speaking males and females, 18-55 (inclusive) years of age
* Normal weight defined as body mass index (BMI) \> 19 and \< 30 kg/m2
* Weight at least 50 kg
* Regular intestinal transit

Exclusion Criteria:

* Evidence of a clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological or psychiatric disease
* Any abnormal value of laboratory, vital signs, 12-lead electrocardiogram or physical exam which may in the opinion of the investigator interfere with the test results or cause a health risk for the subject if he/she takes part into the study
* Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study
* Known hypersensitivity to the active substance(s) or to any of the excipients of the drug
* Pregnant or lactating females
* Recent or current (suspected) drug abuse or positive result in the drugs abuse test
* Recent or current alcohol abuse (regular drinking more than 21 units per week for males and more than 16 units per week for females \[1 unit = 4 cl spirits or equivalent\])
* Current use of nicotine containing products more than 5 cigarettes (or equivalent)/day and/or inability to refrain from the use of nicotine containing products during the study
* Use of caffeine containing beverages more than 600 mg of caffeine/day and/or inability to refrain from the use of caffeine containing beverages during the treatment periods until 24 h after study treatment administration
* Blood donation or loss of significant amount of blood within 90 days prior to the first study treatment administration
* Administration of another investigational drug within 90 days prior to the first study treatment administration
* Unsuitable veins for repeated venipuncture or for cannulation
* Inability to learn the correct inhalation technique
* Inability to participate in all treatment periods
Effect of Nefopam on Remifentanil Induced Postoperative Hyperalgesia

Opioids has been reported to cause hyperalgesia. Opioid induced hyperalgesia (OIH) is defined as paradoxically lowering the threshold of pain after the exposure of opioid. Remifentanil is a short acting opioid that is commonly used during anesthesia and surgery. However, OIH was reported to occur after surgery when large amount of remifentanil was administered. On the other hand, nefopam is a centrally acting, non-opioid analgesic. Nefopam has been reported to have analgesic and anti-hyperalgesic effect.

The investigators hypothesized that nefopam administration could prevent OIH or reduce the severity of OIH. Therefore, the objective of the study is to find out the effect of nefopam on remifentanil induced hyperalgesia in patients undergoing laparoscopic abdominal surgery.


Eligibility Criteria:
Inclusion Criteria:

1. Patients undergoing laparoscopic gastrectomy
2. American Society of Anesthesiologists physical status I or II
3. aged from 20 to 65 years

Exclusion Criteria:

1. Past history of chronic pain
2. Drug or alcohol abuse
3. Psychotic disorder
4. Taking analgesics, anti-epileptics, and anti-depressants.
5. Taking opioids within 24 hrs
6. Renal disease
7. Neuromuscular disease.
8. Moderate to severe cardiovascular disease
9. Pregnant or breast-feeding
Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

Key objectives of this clinical study are to:

* Determine how well intramuscular (IM) olanzapine depot works compared to placebo
* Evaluate the safety and tolerability of IM olanzapine depot compared to placebo
* Evaluate different doses of IM olanzapine depot compared to placebo to identify the best dose(s).


Eligibility Criteria:
Inclusion Criteria:

* Patients must have schizophrenia and be experiencing a psychotic episode
* Each patient must have a level of understanding sufficient to complete all tests and examinations required by the protocol, and to provide informed consent
* Patient must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to the study entry
* Female patients must not be pregnant or breast-feeding
* Female patients must not be experiencing acute, serious or unstable medical conditions other than schizophrenia

Exclusion Criteria:

* Patients who were previously treated with olanzapine and are considered to be treatment-resistant to olanzapine, in the opinion of the investigator
* One or more seizures without a clear and resolved etiology is exclusionary. However, if the patient has had one or more seizures in the past with an identifiable etiology, and that etiology has been resolved, the patient may be entered.
* Treatment with clozapine within 4 weeks prior to visit 1
* DSM-IV or DSM-IV-TR substance (except nicotine and caffeine) dependence within the past 30 days
* Treatment with remoxipride within 6 months (180 days) prior to visit 1
Eating Disorders Clinical Research Network

UK Eating Disorder services are facing unprecedented demand, with effective service delivery hampered by inadequate resources, fragmented services and variable care pathways. Individuals with eating disorders, families and clinicians all agree on the critical need to improve care pathways and treatment, leading to better outcomes.

Eating disorders are serious, complex conditions influenced by a blend of biological, psychological, and environmental factors. The approach of this project is grounded in the "biopsychosocial" model. Recently, anorexia research confirms a genetic component, with biological, metabolic, and psychological mechanisms at play. Further biological research across eating disorders could allow a better understanding of the mechanisms underlying eating disorder development and better, more personalised treatments.

This project will test the feasibility of establishing a UK-wide NHS research network spanning child and adult eating disorder services to enable a step change in the ability to conduct eating disorder research. It will help address fragmentation and facilitate novel biological, psychological, and social research collaborations. The data the investigators gather will be open to all researchers for data analyses, and the collaborations established will form a collaborative network to enable future clinical trials, experimental medicine and psychology.

The study will be conducted at child and adult eating disorder services who opt to join the Network. Participants will be patients receiving treatment for an eating disorder at one of the participating services, and their parents/guardians if applicable.

Participants will complete questionnaires and have blood and other physical tests as specified in the EDCRN dataset. The study will last until 29th October 2026 (the end of the current funding period) and/or when a participant is discharged from treatment, whichever is sooner. For participants discharged before the study ends, there will be an opportunity for patients to complete optional follow-up questionnaires on a periodic basis.


Eligibility Criteria:
Inclusion Criteria:

* Patients who have been diagnosed with an eating disorder under at least 1 of the criteria specified in the DSM-5 and/or ICD-9, 10 or 11.
* Patients who are receiving treatment as inpatients, day-patients or outpatients at a CAMHS or Adult service who is participating in the EDCRN.
* Patients who are receiving treatment in the UK.

OR:

* Parents/guardians of patients who have been diagnosed with an eating disorder under at least 1 of the criteria specified in the DSM-5 and/or ICD-9, 10 or 11.
* Parents/guardians of patients who are receiving treatment as inpatients, day-patients or outpatients at a CAMHS or Adult service who is participating in the EDCRN.
* Parents/guardians of patients who are receiving treatment in the UK.

Exclusion Criteria:

* Individuals who do not meet the criteria specified above will be considered ineligible to participate in the EDCRN.